BioMarin Pharmaceutical announced a long‑term enterprise agreement with Veeva Systems that will broaden the use of Veeva’s cloud platform across the company’s development and commercialization functions.
The deal builds on a history of collaboration and positions BioMarin to accelerate rare‑disease therapy development. It will leverage Veeva Vault, Veeva CRM, and Veeva Development Cloud to streamline regulatory submissions, data management, and go‑to‑market processes.
CEO Alexander Hardy said the agreement will "enable us to bring our transformative medicines more quickly to patients around the world." The partnership follows BioMarin’s $4.8 billion acquisition of Amicus Therapeutics and the discontinuation of BMN 349, underscoring a focus on portfolio optimization and operational efficiency.
While the financial terms of the agreement were not disclosed, the long‑term nature signals a sustained investment in digital infrastructure. By integrating Veeva’s cloud solutions, BioMarin expects to reduce cycle times for regulatory filings and improve data integrity across its rare‑disease pipeline.
Industry analysts view the partnership as a strategic lever for BioMarin’s growth, noting that digital transformation is a key driver for companies competing in the rare‑disease space. The collaboration is expected to enhance BioMarin’s ability to respond quickly to regulatory changes and market demands, potentially accelerating the launch of new therapies.
The partnership also reflects Veeva’s broader role in the life‑sciences sector, where its cloud platform serves over 1,500 customers. By expanding its use of Veeva’s suite, BioMarin aligns itself with a proven technology partner that can support both clinical and commercial functions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.